Clinical trial with an active ingredient of a pharmaceutical specialty marketed in Spain vs. placebo.
Randomized, double-blind, multicenter phase III clinical trial that evaluates the efficacy and safety of dexamethasone compared to placebo in patients with severe influenza.
Aged ≥ 18 years.
Diagnosis of influenza A or B virus infection by antigen or RT-PCR (local laboratory) at the time of entry or at 48 hours prior to randomization in respiratory specimens (nasopharyngeal swab or bronchoalveolar lavage).
Hospitalized patients with an estimated hospital stay of more than 24 hours.
In previous treatment or concomitant start of treatment with oseltamivir.
1. Patients with bronchial hyperresponsiveness that requires systemic corticosteroids for more than 24 hours.